Entries |
Document | Title | Date |
20100261656 | Therapeutic Use of the Encoding Sequence of the Carboxy-Terminal Domain of the Heavy Chain of the Tetanus Toxin - The present invention relates to the therapeutic use of the encoding sequence of the carboxy-terminal domain of the heavy chain of the tetanus toxin and of the polypeptide encoded by said sequence, preferably for the treatment of amyotrophic lateral sclerosis (ALS). | 10-14-2010 |
20100273714 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS - The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus. | 10-28-2010 |
20100279942 | METHODS FOR TREATING MOTOR NEURON DISEASE - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b). | 11-04-2010 |
20100286053 | PLASMINOGEN ACTIVATOR INHIBITOR AMELIORATION OF NEWBORN HYPOXIC ISCHEMIC BRAIN INJURY - Plasminogen activators as potential therapeutic targets in neonatal hypoxia ischemia (HI) brain injury. Use of plasminogen activator inhibitor-1 (PAI-1) to ameliorate HI encephalopathy related disease. Use of PAI-1 as preventive treatment of cerebral palsy (CP). | 11-11-2010 |
20100305040 | PRODUCTION OF SOLUBLE RECOMBINANT PROTEIN BY PI VALUE CONTROL OF N-TERMINAL - The present invention relates to a method for improving secretion efficiency of a recombinant foreign protein using a polypeptide fragment containing N-region of a signal sequence (directional signal) or variants thereof with the controlled pI value and/or a secretional enhancer composed of a hydrophilic polypeptide with the controlled pI value. The method of the present invention can be not only useful for the production of a recombinant foreign protein by preventing precipitation of an insoluble precipitate and by increasing extracellular or extra-periplasmic secretion efficiency of a recombinant protein but also useful for the transduction of an effective therapeutic protein by increasing membrane permeability using a strong secretional enhancer. | 12-02-2010 |
20100311665 | Method and Composition for Potentiating an Opiate Analgesic - Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans. | 12-09-2010 |
20110009329 | METHOD FOR TREATING NEURODEGENERATIVE DISEASES - A method for preventing a break out of a neurodegenerative disease in an individual and for treating an individual suffering from a neurodegenerative disease comprising the administration of an effective amount of an antimicrobial and neurotrophic peptide | 01-13-2011 |
20110009330 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 01-13-2011 |
20110009331 | PROTEIN KINASE C PEPTIDES FOR USE IN WITHDRAWAL - A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ε and/or γ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for εPKC or γPKC and instructions for use. | 01-13-2011 |
20110028401 | CRIPTO BLOCKING MOLECULES AND THERAPEUTIC USES THEREOF - The present invention concerns a monomeric or multimeric tripeptide molecule able of inhibiting Cripto signalling in embryonic stem cells, thereby enhancing dopamine specification and differentiation, after transplantation in animal models of Parkinson's disease, as well as reducing tumor formation, and uses thereof. | 02-03-2011 |
20110053856 | METABOLITE DERIVATIVES OF THE HDAC INHIBITOR FK228 - The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases. | 03-03-2011 |
20110053857 | YEAST CELLS EXPRESSING TAR DNA-BINDING PROTEIN 43 AND USES THEREFOR - Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of the formation or maintenance of cytoplasmic inclusions of TDP-43. Compounds identified by such screens can be used to treat or prevent TDP-43 proteinopathies such as frontotemporal lobar degeneration or amyotrophic lateral sclerosis. | 03-03-2011 |
20110077204 | Agent for Targeted Drug Delivery To Cerebral Neurons - The present invention relates to targeting agents of drugs, more specifically, to targeting agents that cause drugs to be incorporated into brain neurons. The present invention further relates to medicines comprising the targeting agents and drugs. The present invention also relates to a method for targeting drugs to brain neurons. | 03-31-2011 |
20110086804 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-14-2011 |
20110092433 | FGF9-RELATED METHODS FOR TREATING ANXIETY - The present application relates to the treatment of anxiety in a subject. The invention provides novel diagnostic markers and assays, as well as agents and compounds useful for treating patients who suffer from mental illnesses and anxiety disorders. | 04-21-2011 |
20110092434 | MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS - The present invention relates to the use of at least one compound comprising the amino acid sequence: (X | 04-21-2011 |
20110092435 | TREATMENT OF PARKINSON'S DISEASE - Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used in connection with gene therapeutic techniques or direct peptide injection for the aforementioned indications. Kits useful in practicing the inventive method are also disclosed, as are animal models useful for studying various neurodegenerative conditions. | 04-21-2011 |
20110092436 | COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ). | 04-21-2011 |
20110098226 | Small molecular weight TNF receptor multimeric molecule - The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct. The invention also relates to a method of inhibiting the biological activity of TNF in a host comprising administering to the host an effective amount of a receptor molecule of the present invention. The invention further relates to receptor molecules which bind cytokines that bind to receptor molecules comprising more than one subunit. | 04-28-2011 |
20110105402 | Silk Peptide For Improving Neuroprotective And Neurofunctional Effects And A Method Of Its Prepartion - A silk peptide having neuroprotective and neurofunctional activities and its preparation method are discussed. One method relates to preparing silk protein preferably having neuroprotective activity with weight average molecular weight of 200-100,000 by hydrolysis of silk fibroin; also discussed are a composition for preventing or treating brain disease comprising silk peptide and pharmaceutically acceptable carrier, and a composition for improving brain function. | 05-05-2011 |
20110105403 | PEPTIDES - The present invention discloses cell penetrating peptides and conjugates of a cell penetrating peptide and a cargo molecule. | 05-05-2011 |
20110130336 | METHOD OF TREATING ISCHEMIC INJURY USING APOAEQUORIN - Compositions containing apoaequorin and methods for their use in treating ischemic injury, particularly reduction in neuronal cell death following ischemic insult, are provided by the present invention. | 06-02-2011 |
20110130337 | POLYMORPHISMS ASSOCIATED WITH PARKINSON'S DISEASE - The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD. | 06-02-2011 |
20110160138 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, the composition comprising, as an active ingredient, X-Met-His-Gln-Pro-His-Gln-Pro-Leu-Pro-Pro-Thr-Val-Met-Phe-Pro-Pro-Gln-Ser-Val-Leu (SEQ ID NO: 6) or a salt thereof, wherein X is absent or represents Ser-Trp or Leu-Gln-Ser-Trp (SEQ ID NO: 7). | 06-30-2011 |
20110160139 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Val-Arg-Gly-Pro-Phe-Pro-Ile-Ile-Val (SEQ ID NO: 5), wherein X is absent or represents Pro. | 06-30-2011 |
20110172159 | PROTEIC ACID POLYMER, PRODUCTION PROCESSES, USE OF PROTEIC ACID POLYMER, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT - The present invention relates to proteic acid polymers (pLNs) comprising specific properties to reduce tissue damage and improve functional recovery after injury, and the production process of said proteic acid polymers. Those pLNs are preferably obtained using the protein laminin diluted in an acidic pH in the presence of divalent cation. The use of said proteic acid polymers for the production of a drug, a pharmaceutical composition containing such pLNs and a method of treatment of animals affected by traumatic, degenerative or inflammatory tissue injuries in nervous tissue, muscle, epithelial and connective tissues in general are also objects of the present invention. | 07-14-2011 |
20110178022 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION - The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated. Alternatively the compound of the invention comprises a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, where the first and second peptide or peptide analogue each comprise at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof. | 07-21-2011 |
20110183910 | BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 07-28-2011 |
20110183911 | METHOD FOR IMPROVING NEUROTRANSMISSION FAILURE USING A NOVEL AGENT - A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for ameliorating neurotransmission dysfunction diseases caused by various pathological conditions is provided. | 07-28-2011 |
20110190213 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-3 - The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native IL-3 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 08-04-2011 |
20110190214 | Advantageous Salts of Mu-Opiate Receptor Peptides - The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions. | 08-04-2011 |
20110190215 | THERAPEUTIC USE OF PEPTIDES - The amino acid sequences of peptides are disclosed. These peptides, and combinations thereof, are useful, inter alia, for the treatment of obesity, type II diabetes mellitus, hypertension, central nervous system disorders, dementia, Alzheimer's disease, asthma, and cancer, | 08-04-2011 |
20110190216 | MATERIALS AND METHODS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY AND TAXANE-INDUCED PERIPHERAL NEUROPATHY (TIPN) - The present invention concerns materials and methods for treating, inhibiting the progression or, and/or preventing a disorder associated with and/or characterized by neuronal degeneration, such as SMA or TIPN, in a person or animal. One aspect of the invention pertains to a fusion protein comprising: i) an SMN polypeptide portion, or a fragment or variant thereof having SMN biological activity, and ii) a non-toxic BoTN portion, or a fragment or variant thereof capable of providing for receptor-mediated endocytosis in a cell, such as a neuron. In one embodiment, the SMN protein is a human SMN1 protein. In one embodiment, the BoTN portion comprises the BoTN heavy chain, or a fragment or variant thereof capable of providing for receptor-mediated endocytosis in a cell. The non-toxic BoTN portion can optionally comprise a modified and/or hybrid polypeptide that comprises amino acid sequences or polypeptides from non-BoTN proteins or polypeptides and optionally BoTN polypeptides. For example, in one embodiment, a non-toxic BoTN portion of the invention comprises a non-toxic portion of a diphtheria toxin and/or tetanus toxin. | 08-04-2011 |
20110195907 | AMINO ACID AND PEPTIDE CONJUGATES OF AMILORIDE AND METHODS OF USE THEREOF - The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the treatment of a central nervous system disease or disorder or for the prevention or reduction of ischemia-reperfusion injury using the amiloride conjugates of the present invention. | 08-11-2011 |
20110195908 | PROSAPOSIN AS A NEUROTROPHIC FACTOR - Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons. | 08-11-2011 |
20110224145 | Neuromodulators and Methods of Use - The present disclosure provides neuromodulators, nucleic acid encoding thereof, and compositions thereof for endowing visual processing abilities to neuronal cells. The present disclosure further provides a method of restoring light sensitivity to degenerate retinas. | 09-15-2011 |
20110224146 | AUGMENTED COGNITIVE TRAINING - The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents. | 09-15-2011 |
20110230414 | Pyrrolopyrazine Kinase Inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, | 09-22-2011 |
20110230415 | Pharmaceutical Composition Containing GHRP-6 To Prevent And Eliminate Fibrosis And Other Pathological Deposits In Tissues - The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma. | 09-22-2011 |
20110288029 | METHOD FOR INHIBITING NEURONAL CELL DEATH - This invention relates to a method of inhibiting neuronal cell death, including protecting neronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C Associate Peptide (TCAP). The invention provides the use of TCAP to prevent and/or treat a number of brain conditions, such as hypoxia-ischemia and brain alkalosis. In another aspect, the invention provides a method of treating various pH induced neuronal conditions. | 11-24-2011 |
20110294740 | TREATMENT OF AMYLOIDOSES USING MYELIN BASIC PROTEIN AND FRAGMENTS THEREOF - In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibril lization of peptides implicated in the amyloidoses, especially the amyloid-beta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide methods of identifying substances that modulate the interference. Further embodiments provide methods of preventing amyloidoses, especially AD and CAA by administering myelin basic proteins or fragments thereof. | 12-01-2011 |
20110306556 | NEUROPROTECTION FROM BRAIN ANOXIA AND REPERFUSION INJURY DURING STROKE AND COMPOSITIONS OF PKG PATHWAY ACTIVATORS AND METHOD OF USE THEREOF - A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway. | 12-15-2011 |
20110312893 | METHOD FOR ISOLATING NEURAL CELLS WITH TENASCIN-R COMPOUNDS - The invention relates to a method for isolating neural cells using tenascin-R compounds, tenascin-R fragments particularly suited for said method and tenascin-R fusion proteins, to recombinant preparation of said tenascin-R compounds, and to a kit for carrying out said method and to the use of said method for preparing high-purity neural cell populations. The invention further relates to antibodies suitable for detecting and isolating tenascin-R compounds. | 12-22-2011 |
20110312894 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASES - The present invention relates to methods of diagnosing, treating and prognosing mental disorders, such as Alzheimer's Disease. In one embodiment, the present invention provides a method of treating Alzheimer's Disease by inhibiting dysfunctional signaling of α7 nAChRs in the medial septum region of an individual. | 12-22-2011 |
20120004178 | BIGLYCAN MUTANTS AND RELATED THERAPEUTICS AND METHODS OF USE - The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 01-05-2012 |
20120015883 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods ofusing same - Novel peptide/peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: | 01-19-2012 |
20120015884 | Polypeptides for Specific Targeting to Otx2 Target Cells - The invention relates to polypeptides which enable the specific targeting of a molecule of interest to homeoprotein Otx2 target cells. These polypeptides are defined by the general sequence: B | 01-19-2012 |
20120028904 | METHODS, SYSTEMS, AND COMPOSITIONS FOR CALPAIN INHABITION - Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains. | 02-02-2012 |
20120028905 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A - Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed. | 02-02-2012 |
20120035112 | NEURONAL DIFFERENTIATION-INDUCING PEPTIDE AND USE THEREOF - A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide. | 02-09-2012 |
20120040910 | METHODS OF PREVENTING OR TREATING BRAIN DISEASES - The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient. | 02-16-2012 |
20120058949 | Methods of Treating Neurological Disorders - The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway. | 03-08-2012 |
20120065141 | STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS - Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a | 03-15-2012 |
20120065142 | NOVEL SOLID MATERIALS OF AND METHODS FOR OBTAINING THEM - The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals. | 03-15-2012 |
20120065143 | Dose and localization of botulinum toxins in skin and muscle - A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight. | 03-15-2012 |
20120071415 | DOMINANT NEGATIVE MUTANTS OF SAM68 FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) - The present invention relates to the use of dominant negative mutants of Sam68 for the manufacture of a medicament for the treatment of spinal muscular atrophy, to nucleic acids coding for such mutants and to vectors and methods related thereto. | 03-22-2012 |
20120077751 | Methods for modulating neuronal responses - The invention provides, in part, methods and reagents for modulating neuronal apoptosis and for modulating synaptic plasticity. | 03-29-2012 |
20120077752 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, Phe-Pro. | 03-29-2012 |
20120077753 | JNK INHIBITORS FOR USE IN TREATING SPINAL MUSCULAR ATROPHY - The brain specific isoform (JNK3) of c-Jun NH2-terminal kinase (JNK) has been found to mediate the degeneration of spinal motor neurons caused by SMN deficiency in spinal muscular atrophy (SMA). Moreover, the ability of JNK inhibitors to reduce degeneration of neurons lacking SMN is also disclosed. The JNK signaling pathway can therefore mediate neurode-generation in SMA and represents a therapeutic target for treatment of SMA. | 03-29-2012 |
20120083450 | CEREBROPROTEIN HYDROLYSATE FOR TREATING BRAIN INJURIES AND NEURODEGENERATIVE CONDITIONS EFFECTING THE BRAIN - Cerebroprotein hydrolysate is administered intravenously and/or orally to help treat a range of brain injuries and neurodegenerative conditions effecting the brain including Traumatic Brain Injury (TBI), concussions, injuries resulting from automobile accidents, sports injuries, falls that impact the head, accidents and acts of violence that impact the head and brain including injuries incurred from combat related activities, Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, and other neurological conditions that adversely effect the function of the brain and central nervous system. The types of brain injuries and neurodegenerative conditions that may be treated with cerebroprotein hydrolysate range from mild to severe. Cerebroprotein hydrolysate treatment effectively assists the brain in rebuilding neurons, synapses, and neurological tissue by infusing the brain with specific proteins, neuropeptides, and amino acids to assist with brain repair. | 04-05-2012 |
20120083451 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein X represent Val, Ile or Asn-Ile and Y represent Phe or Leu. | 04-05-2012 |
20120088731 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH REGULATING VDAC1 PROTEIN - The present invention provides a method for curing Parkinson's disease through regulating VDAC1 (voltage-dependent anion channel 1) protein. Specifically, the present invention provides a pharmaceutical composition for curing PD comprising a VDAC1 protein regulator. The VDAC1 protein regulators comprise an inhibitor of VDAC1 mRNA production, an inhibitor of mitochondrial permeability transition pore (mPTP) formation, and a mitochondrial calcium uptake inhibitor. In addition, the present invention provides a method for curing Parkinson's disease comprising administering a VDAC1 protein regulator to a subject with Parkinson's disease. The present invention could provide a method for curing Parkinson's disease through preventing and/or restoring mitochondrial dysfunction. | 04-12-2012 |
20120088732 | THERAPEUTIC COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 04-12-2012 |
20120094915 | ANTI-MENTAL FATIGUE DRUG - To provide anti-mental fatigue drugs as well as foods, beverages, and fodders that can be taken daily and effective for relieving mental stress and inducing relaxation by intake. An anti-mental fatigue drug containing iron-binding lactoferrin as an active ingredient and foods, beverages, and fodders containing the drug. | 04-19-2012 |
20120094916 | ALTERING MEMORY BY AFFECTING STAUFEN FUNCTION - The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or STAUFEN function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating staufen-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation associated with a defect in STAUFEN and methods for treating a defect in performance of a hippocampal-dependent cognitive task associated with a defect in STAUFEN. | 04-19-2012 |
20120108517 | Agents and methods for denervation - Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. | 05-03-2012 |
20120129781 | COMPOSITION COMPRISING ALPHA-LIPOIC ACID AND CARNOSINE FOR TREATING THE PHANTOM LIMB SYNDROME - The present invention relates to a composition comprising an effective amount of α-lipoic and carnosine, or pharmaceutically acceptable derivatives thereof for treating the phantom limb syndrome. The present invention also relates to the use of such a composition for treating the phantom limb syndrome. | 05-24-2012 |
20120135936 | INHIBITION OF PRION PROTEIN PROPAGATION BY RECEPTOR ASSOCIATED PROTEIN (RAP), ITS DERIVATIVES, MIMETICS AND SYNTHETIC PEPTIDES - A pharmaceutical formulation and method of treatment of prion disease include a RAP agent with a pharmaceutically acceptable carrier and/or excipient, and the administration of same to a subject suffering from or at risk of a prion disease. The RAP agent is an effective means for the prevention and/or treatment of various prion diseases regardless whether the disease is acquired by infection or by genetic mutation. | 05-31-2012 |
20120142602 | Composition and Method for Preventing or Treating a Tauopathy - The present invention is a composition and method for the prevention and treatment of a tauopathy. The composition of the invention includes N-terminal amino acid residues of the tau protein, which have been identified as being involved in toxic activation of a PP1/GSK3 signaling cascade and inhibition of fast axonal transport in human tauopathies. | 06-07-2012 |
20120142603 | BIOADHESIVE PATCH FOR SUTURELESS CLOSURE OF SOFT TISSUE - Provided herein are compositions and methods for treating soft tissue injuries using a patch having a polymer on its surface linked to polypeptides having a disintegrin domain. The polypeptides having a disintegrin domain can include contortrostatin, vicrostatin, and ADAM derived polypeptides. Compositions of the invention can be used for the treatment of injuries to soft tissues that include the eye, liver and brain. | 06-07-2012 |
20120149645 | COMPOSITIONS AND MODULATION OF MYOCYTE ENHANCER FACTOR 2 (MEF2) - The disclosure relates to mitochondrial myocyte enhancer factor 2 (MEF2), Parkinson's disease, and other related diseases. In certain embodiments, the disclosure relates to analyzing the levels of mitochondrial MEF2 isoforms and/or its mitochondrial target gene ND6 in peripheral blood cells such as white blood cells as an indicator for neuronal mitochondrial MEF2 or ND6 and correlated the level to disease diagnosis, treatment, and prognosis. | 06-14-2012 |
20120178696 | Compositions and Methods for Modulating AMPA Receptor-mediated Excitotoxicity - The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1-3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are nucleotide sequences encoding the polypeptides, methods of inhibiting GAPDH association with the GluR2 subunit or p53. Methods of inhibiting AMPA receptor mediated excitotoxicity using the polypeptides and nucleic acids are also disclosed. | 07-12-2012 |
20120202745 | ADULT CEREBELLUM-DERIVED NEURAL STEM CELLS AND COMPOSITIONS AND METHODS FOR PRODUCING OLIGODENDROCYTES - This disclosure describes a novel population of cerebellum-derived neural stem cells that can be isolated from the adult brain, expanded, and differentiated into neurons, astrocytes and oligodendrocytes. This disclosure also describes compositions and methods for producing oligodendrocytes. Oligodendrocytes can be produced in vitro (e.g., in culture) or in vivo (e.g., for therapy or in a non-human transgenic animal) using the compositions and methods described herein. | 08-09-2012 |
20120208764 | METHOD AND COMPOSITIONS FOR TREATING STROKE WITH FEVER - The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemia by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient. | 08-16-2012 |
20120208765 | MODIFIED AGRIN-FRAGMENT CAPABLE OF RESTORING MUSCLE STRENGTH FOR USE AS A MEDICAMENT - Modified agrin fragment having in vivo activity, comprising at least the domains LG2 and LG3 of human agrin in covalently interlinked form and modified in such a way that the fragment cannot be cleaved by neurotrypsin for use as medicament. | 08-16-2012 |
20120220533 | MODULATING NEUROMUSCULAR JUNCTION DENSITY CHANGES IN BOTULINUM-TOXIN TREATED TISSUE - A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is periodically administered to the tissue of the patient and/or the neuropeptide of the CRF family is periodically administered to the tissue of the patient. The periods with which the botulinum toxin and the neuropeptide of the CRF family are administered may be the same or may be different. In some examples, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at substantially the same time, while in other embodiments, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at different times. | 08-30-2012 |
20120238503 | HUMAN LAMININ ALPHA2 CHAIN LG3 DOMAIN AND ACTIVE PEPTIDES PROMOTING CELL ADHESION, SPREADING, MIGRATION, AND NEURITE OUTGROWTH - The present invention relates to human laminin α2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin α2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKCδ and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration. | 09-20-2012 |
20120245093 | Neuronal Viability Factor and Use Thereof - This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides. | 09-27-2012 |
20120245094 | COMPOUNDS, COMPOSITIONS AND USE - A peptide comprising a unit of formula (I) and having a molecular weight of less than 2000 wherein each X is independently an organic group, e.g. a C | 09-27-2012 |
20120245095 | BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 09-27-2012 |
20120270794 | POLYMORPHISMS ASSOCIATED WITH PARKINSON'S DISEASE - The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD. | 10-25-2012 |
20120277160 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - Provided are a composition for improving the brain function, which can be orally taken at a low dose, and a method therefor. The composition for improving the brain function contains, as the active ingredient, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Ile or Asn-Ile; and Y is nil or represents Val-Met), X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is abscent or represents Thr-Gln-Thr-Pro, Pro-Leu-Thr-Gln-Thr-Pro, Leu-Thr-Gln-Thr-Pro or Pro; and Y is abscent or represents Val-Met), or a salt of the same. The method for improving the brain function comprises administering said peptide or a salt of the same. | 11-01-2012 |
20120309687 | Glioprotectant Peptide for Use in the Treatment of Amyotrophic Lateral Sclerosis (ALS) and Methods Related Thereto - The described invention relates to the use of the TAT-BH4 peptide for treating or preventing the progression of ALS. The methods include, postponing the appearance of symptoms and improving motor performance and survival in ALS. Methods are also provided, wherein the TAT-BH4 peptide is in a composition further comprising a pharmaceutically acceptable excipient. | 12-06-2012 |
20120309688 | PEPTIDE SUBSTANCE STIMULATING REGENERATION OF CENTRAL NERVOUS SYSTEM NEURONS, PHARMACEUTICAL COMPOSITION ON ITS BASE, AND THE METHOD OF ITS APPLICATION - Disclosed is a method of treating diseases. traumas. as well as consequences of traumas of the central nervous system. and a method for stimulating neurons regeneration. which involves the use of a peptide glutamyl-aspartyl-arginine. Also disclosed are a pharmaceutical composition containing the above peptide and a pharmaceutically acceptable carrier and a method of stimulating the regeneration of neurons by administering to a patient a pharmaceutical composition containing the above peptide in the dose of 0.01-100 μg/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect. such administration being performed parenterally. | 12-06-2012 |
20120316120 | FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF - Fluorinated compounds and methods of making fluorinated compounds are described herein. | 12-13-2012 |
20120329721 | MEANS FOR PREVENTING AND TREATING CELLULAR DEATH AND THEIR BIOLOGICAL APPLICATIONS - Inhibitors for preventing, blacking/silencing caspase-2 activity in cell death. | 12-27-2012 |
20120329722 | METHOD FOR ENZYMATICALLY PREPARING PEPTIDES FOR USE IN IMPROVEMENT OF BRAIN FUNCTION - The invention provides a method for preparing a peptide for improving brain function, comprising hydrolyzing milk casein with an enzymatic catalyst comprising a protease to produce a hydrolysate comprising: (i) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a variant thereof; (ii) a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2 or a variant thereof; or (iii) a mixture of the peptides of (i) and (ii), wherein the production yield of each of the peptides is 2% or more, or the total production yield of the mixture is 10% or more. The invention also provides a food or drink or a pharmaceutical composition containing the hydrolysate. | 12-27-2012 |
20130012447 | PROTEIN KINASE C-DELTA INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION - The invention relates to the use of δPKC inhibitor peptides to treat brain injury, particularly traumatic brain injury (TBI). In one embodiment, peptide that specifically inhibit δPKC are used to protect neurological tissue by promoting astrocyte proliferation. | 01-10-2013 |
20130035294 | Neuromedin and FN-38 Peptides for Psychotic Diseases - Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders. | 02-07-2013 |
20130053324 | NOVEL SELF-ASSEMBLING PEPTIDES AND THEIR USE IN THE FORMATION OF HYDROGELS - There is described a group of novel self-assembling peptides (SAPs), comprising biotinylated and unbiotinylated sequences, hybrid peptide-peptoid sequences, branched sequences for a total of 48 tested motifs, showing a heterogeneous ensemble of spontaneously self-assembled structures at the nano- and microscale, ranging from short tabular fibers to twisted ribbons, nanotubes and hierarchical self-assembled micrometer-long sheets. Specifically, the SAPs according to the present invention which initially spontaneous assemble, surprisingly form stable solid scaffolds upon exposure to neutral pH buffer. Further these SAPs allow adhesion, proliferation and differentiation of murine and human neural stem cells and have self-healing propensity. They also did not exert toxic effects in the central nervous system, can stop bleeding and foster nervous regeneration. Therefore, the SAPs according to the present invention are improved biomaterials, a highly valid and useful alternative which may replace the known SAPs, thus overcoming the disadvantages related thereto. | 02-28-2013 |
20130059787 | METHODS OF USING HUMAN PROTEIN KINASE C DELTA VIII AS A BIOMARKER - RA treatment can improve cognition; promote neurogenesis; and regulate alternative splicing of genes, particularly by mediating mechanisms of 5′ splice site selection and generation of PKCδ alternatively spliced variants. Expression of PKCδVIII is an indicator of the levels of on-going apoptosis in neurons. In the aging brain, switching the isoform expression to PKCδVIII by RA could shield the cells from neuronal death. The inventors discovered that human PKCδVIII expression is increased in neuronal cancer and decreased in Alzheimer's disease. The data shows that PKCδVIII promotes neuronal survival and increases neurogenesis via Bcl2 and Bcl-xL. In addition, the trans-factor SC35 was found to be crucial in mediating the effects of RA on alternative splicing of PKCδVIII mRNA in neurons. The data described herein indicate that PKCδVIII can be used as a biomarker for neurological diseases such as cancers and Alzheimer's disease and as a tool for monitoring and evaluating treatment. | 03-07-2013 |
20130079286 | MUTEINS OF HUMAN LIPOCALIN 2 (LCNC,HNGAL) WITH AFFINITY FOR A GIVEN TARGET - The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature. | 03-28-2013 |
20130096065 | NEUBLASTIN VARIANTS - Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal. | 04-18-2013 |
20130116191 | TRANSPORT PROTEIN WHICH IS USED TO INTRODUCE CHEMICAL COMPOUNDS INTO NERVE CELLS - The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 05-09-2013 |
20130123187 | PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 05-16-2013 |
20130165385 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 06-27-2013 |
20130165386 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS - Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs). | 06-27-2013 |
20130190247 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 07-25-2013 |
20130196924 | BIOMARKERS FOR DIAGNOSING AND DETECTING THE PROGRESSION OF NEURODEGENERATIVE DISORDERS, IN PARTICULAR OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to biomarkers, to their use and to a method for diagnosing in vitro or detecting the progression of a neurodegenerative disease in an individual, in particular for Amyotrophic Lateral Sclerosis (ALS). The method comprises the steps of isolating a biological sample from the individual; quantifying the level of one or more polypeptides in the biological sample according to the invention; comparing the obtained level with a reference level. | 08-01-2013 |
20130196925 | COMPOSITIONS AND METHODS USEFUL IN ENHANCEMENT OF MEMORY - Compounds derived from a transduction complex that enhance memory in mammals and methods of enhancing memory using said compounds are disclosed. | 08-01-2013 |
20130210739 | BHLH PROTEINS AND THEIR USE AS DRUGS - The present invention relates to at least one protein belonging to the bHLH family and/or at least a nucleic acid molecule coding for the bHLH proteins as drug. | 08-15-2013 |
20130231289 | SYNTHETIC ANALOGUES OF NEURAL REGENERATION PEPTIDES - Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing β-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis. | 09-05-2013 |
20130244945 | LISSENCEPHALY THERAPEUTIC AGENT - An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): | 09-19-2013 |
20130267470 | Treatment Of Penetrative Injury To The Brain - The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel). | 10-10-2013 |
20130288976 | Methods for Determining the Presence or Risk of Developing Facioscapulohumeral Dystrophy (FSHD) - In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene, wherein a determination of the absence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject does not have a genetic predisposition to develop, and is not suffering from FSHD, and/or wherein a determination of the presence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD). | 10-31-2013 |
20130288977 | METHOD OF REGULATING NEURONAL AXON ELONGATION - The present invention includes a treating step of treating neuronal growth cone with a regulatory factor to regulate macropinocytosis caused by a repulsive axon guidance molecule. The present invention can provide a new neuronal axon elongation regulating method etc. | 10-31-2013 |
20130324474 | VARIANTS OF HUMAN GDNF - The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use. | 12-05-2013 |
20130331328 | SMALL MOLECULE INHIBITORS OF AGBL2 - Small molecule inhibitors of AGBL2 are provided, as well as methods of using the inhibitors to treat or prevent cancer and neurologic disorders. | 12-12-2013 |
20130331329 | BIOMARKERS FOR SEIZURES - The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits. | 12-12-2013 |
20140018299 | METHOD AND DEVICE TO DETECT, MONITOR AND PROMOTE NEURAL REGENERATION AND IMPROVEMENT OF COGNITIVE FUNCTION IN A SUBJECT SUFFERING FROM NEURAL INJURY - Severe traumatic brain (TBI) injuries are often associated with long-term and disabling consequences. Prognosis and chronic treatment planning following severe TBI remain challenging. The discovery of specific brain biomarkers could create new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. The present invention provides a method of detection of Microtubule-associated protein-2 (MAP-2), a marker of dendritic damage, in a biological sample of survivors after TBI and evaluates the recovery of the patient, including an improvement in cognitive abilities and function. | 01-16-2014 |
20140024597 | INTRANASAL DELIVERY OF CELL PERMEANT THERAPEUTICS - The present invention relates to compositions and methods for the inhibition of apoptosis associated with ischemic injury in the central nervous system. In addition, the present invention relates to compositions and methods useful for extending the therapeutic window associated with ischemic injury. | 01-23-2014 |
20140024598 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS - Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder. | 01-23-2014 |
20140024599 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE OR INJURY OF THE NERVOUS SYSTEM - Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell. | 01-23-2014 |
20140038896 | Retroelements and mental disorders and methods of measuring L1 retrotransposition - A method of treating increased non-LTR retrotransposition in a cell. The method includes exposing a neural cell to a retrotransposition inhibitor in an amount sufficient to decrease the non-LTR retrotransposition in the neural cell or a progeny of the neural cell. In various embodiments, the non-LTR retrotransposition involves at least one L1 retrotransposon. Also provided is a method of assaying retrotransposition in neural cells. The method includes sorting synchronized neural cells of the same genetic background into single neural cells, and subjecting one or more of the sorted single neural cells to quantitative polymerase chain reaction amplification of at least one retrotransposon. In addition, a method of identifying an inhibitor of retrotransposition and a identifying a neural condition associated with non-LTR retrotransposition are provided. | 02-06-2014 |
20140038897 | TFEB VARIANTS AND USES THEREOF - The invention refers to TFEB related molecules, as variants, mutants, truncated proteins, chimeras etc. that are constitutively localized in the nucleus of a eukaryote cell. Such molecules have a therapeutic applicability in all of disorders that need of an induction of the cell authophagic/lysosomal system, as lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases and metabolic diseases. | 02-06-2014 |
20140045762 | MOLECULAR SWITCH FOR NEURONAL OUTGROWTH - Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase δ (RPTPδ), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTPδ and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTPδ. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTPδ. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury. | 02-13-2014 |
20140045763 | COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI) - The current invention provides new compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington's disease-like 2 caused by expansions of CUG repeats in the transcripts of DM1/DMPK, SCA8 or JPH3 genes. | 02-13-2014 |
20140073576 | METHODS OF PREVENTING OR TREATING BRAIN DISEASES - The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient. | 03-13-2014 |
20140088017 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME - The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers. | 03-27-2014 |
20140094413 | HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS - Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, Alzheimer's disease, Parkinson's disease, amyotrphic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury, diabetes and metabolic syndrome, cancer, and defective wound healing. | 04-03-2014 |
20140100169 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 04-10-2014 |
20140121166 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF JUVENILE NEURONAL CEROID LIPOFUSCINOSIS AND RELATED DISORDERS - Provided are materials and methods for the prevention and treatment of Juvenile Neuronal Ceroid Lipofuscinosis comprising administration of an effective amount of at least one of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor. In some embodiments, the methods comprise administration of an effective amount of each of a hemi-channel inhibitor and a phosphodiesterase-4 inhibitor. Also provided are pharmaceutical compositions comprising a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor, as well as kits comprising at least one effective dose of a hemi-channel inhibitor or a phosphodiesterase-4 inhibitor or a combination of both. | 05-01-2014 |
20140121167 | THERAPEUTIC PEPTIDES AND USE THEREOF AGAINST HUNTINGTON'S DISEASE - Novel therapeutic compounds for use against Huntington's disease. More especially, an isolated peptide of size less than 100 amino acids and containing:
| 05-01-2014 |
20140179614 | Metallothionein-Derived Peptide Fragments - The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment. | 06-26-2014 |
20140213526 | SMALL SURVIVAL-PROMOTING/IMMUNOMODULATORY PEPTIDE FOR TREATMENT OF BRAIN DAMAGE, NEURODEGENERATIVE DISORDERS, AND INFLAMMATORY DISORDERS - A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided. | 07-31-2014 |
20140288004 | LACTOFERRIN AND THE WHITE MATTER - The present invention generally relates to white matter. In particular, the present invention relates to a composition that can be used for promotion the development and/or void loss of white matter. One embodiment of the present invention relates to a composition comprising lactoferrin for use in the promotion of the development of the white matter, in the treatment or prevention of a delayed development of the white matter, and or in the treatment of prevention of a loss of white matter. | 09-25-2014 |
20140296152 | Stem Cell Derived Factors for Treating Pathologic Conditions - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions. | 10-02-2014 |
20140303088 | HSP20 Inhibits Amyloidogenesis and Neurotoxicity - The present invention compositions and methods of using at least a portions of an isolated and purified α-crystallin polypeptide that includes one or more β-pleated sheets and that prevents neurotoxicity and amyloidogenesis. | 10-09-2014 |
20140309172 | ICE INHIBITING COMPOUNDS AND USES THEREOF - The present disclosure identifies caspase-1/ICE as a therapeutic target for α-synuclein associated diseases and disorders. Related methods and compositions are also provided. | 10-16-2014 |
20140315820 | High-Potency Botulinum Toxin Formulations - The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD | 10-23-2014 |
20140315821 | TREATMENTS INVOLVING ESLICARBAZEPINE ACETATE OR ESLICARBAZEPINE - The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures. | 10-23-2014 |
20140315822 | HIGH MAST2-AFFINITY POLYPEPTIDES AND USES THEREOF - The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, said polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions comprising the same. The invention is also directed to the use of said polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule. | 10-23-2014 |
20140323409 | APOTRANSFERRIN FOR THE TREATMENT OF BRAIN STROKE - The present invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain stroke. Particularly the invention relates to the use of apotransferrin for the preparation of a medicament for the treatment of brain strokes wherein the drug prepared with apotransferrin is for administration by vascular route, preferably intravenous or intraarterial. | 10-30-2014 |
20140329757 | TUBULIN-INTERACTING PROTEIN, CALTUBIN, PROMOTES AXONAL GROWTH - A novel isolated protein, referred to herein as “caltubin”, is provided. Caltubin promotes axonal regeneration, and prevents or at least reduces axonal retraction in neurons. | 11-06-2014 |
20140336126 | OPTINEURIN-DERIVED POLYPEPTIDES, THEIR NUCLEIC ACIDS AND USES THEREOF - The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in SEQ ID no2 to the exclusion of the wild-type Optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind Rab8 protein, when the latter are associated with the Golgi apparatus of a cell, the capacity to bind MYPT1 protein, when said protein is engaged in a Myosin-Phosphatase (MP) complex, the capacity to be phosphorylated by Plk1. The invention also relates to nucleic acid molecule(s) encoding such polypeptide(s), vector(s) and method(s) of production thereof, alteration(s). | 11-13-2014 |
20140342992 | Cell-Penetrating Peptides Having a Central Hydrophobic Domain - The present invention discloses cell penetrating peptides (CPP or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based theraputics, such as polynucleotides, oligonucleotides and peptide nucleic acids. A CPPs of the invention provides a balance between good cell entry efficency and low toxicity and comprises three contiguous domains: the central one being hydrophobic and the flanking ones consisting of arginine and aminohexanoic acid or beta-alanine residues. The hydrophobic domain contains a sequence selected from YQFLI, YRFLI, IQFLI and IRFLI. | 11-20-2014 |
20140349942 | METHODS FOR REDUCING OXIDATIVE DAMAGE - The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (p | 11-27-2014 |
20140357569 | CYCLOSPORIN CONJUGATES - A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R | 12-04-2014 |
20140357570 | COMPOSITIONS COMPRISING NECROSIS INHIBITORS, SUCH AS NECROSTATINS, ALONE OR IN COMBINATION, FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION, THEREBY TREATING CNS DISORDERS - Provided are methods for promoting axon regeneration of a Central Nervous System (CNS) neuron and promoting nerve function following injury to a CNS neuron, for example, brain and/or spinal cord injury. Axon regeneration in a CNS neuron or nerve function following injury to a CNS neuron can be promoted by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject suffering from a CNS disorder, wherein a symptom of the CNS disorder is axon degeneration. | 12-04-2014 |
20140357571 | GLUTAMINE ENRICHED NUTRITIONAL COMPOSITION FOR PRETERM INFANTS - The present invention relates to the use of nutritional compositions enriched in glutamine to improve structural and functional brain development in preterm and/or low birth weight infants. | 12-04-2014 |
20140357572 | NEUROTROPHIC PEPTIDES FOR THE TREATMENT OF TAUOPATHIES - Peptide 6 and in particular, Peptide 021, may be used to treat tauopathies, such as frontotemporal dementia with Parkinsonism linked to chromosome-17 (FTDP-17) tau, corticobasal degeneration, Pick disease, progressive supranuclear palsy, Guam Parkinsonism dementia complex, dementia pugilistica also known as traumatic encephalopathy or traumatic brain injury, ceroid neuronal lipofusinosis, Hallerworden Sptaz disease, Alzheimer's disease, and adults with Down syndrome. | 12-04-2014 |
20140364373 | NOVEL ENTERIC COMBINATION THERAPY - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-Clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-Clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-Clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-Clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 12-11-2014 |
20150018281 | Compositions and Methods for Uncoupling TrkB Receptor from PLC gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures. | 01-15-2015 |
20150018282 | PREPARATION FOR IMPROVING MEMORY AND LEARNING AND USE THEREOF - The invention relates to a preparation for improving memory and learning comprising enzymatic protein hydrolyzate of animal nervous tissue, preferably the tissue of spinal cord of animals for slaughter, while the preferred protein being a myelin protein. The invention also relates to composition for use in treatment of memory disorders, in particular age associated memory disorders and learning impairment. Also disclosed is the method for improving memory and learning. | 01-15-2015 |
20150031623 | THROMBOPOIETIN RECEPTOR LIGANDS FOR NEUROPROTECTION - The present invention provides therapeutic modalities for the treatment of an ischemic event (e.g., stroke) that creates or embodies a risk of neurological damage in CNS sites by administration of a thrombopoietin receptor ligand. | 01-29-2015 |
20150087594 | INDUCED NEURAL STEM CELLS - The present invention relates to a method of deriving an induced neural stem cell (iNCS) by nuclear reprogramming of a somatic cell, wherein the method comprises a step of contacting the somatic cell with Oct4 protein or a functionally equivalent analogue, variant or fragment thereof for a limited time period, as well as an induced neural stem cell obtained by this method. | 03-26-2015 |
20150099706 | TREATMENT OF ISCHEMIC STROKE WITH DRa1-MOG-35-55 - Methods and compositions used in treating ischemic stroke using a recombinant DRα-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DRα-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had or is at risk of developing ischemic stroke. | 04-09-2015 |
20150133387 | Modulation of Synaptogenesis - Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis. | 05-14-2015 |
20150141345 | NOVEL COMPOUNDS AND METHODS FOR INHIBITING CELL DEATH - This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described. | 05-21-2015 |
20150322110 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION - Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipetide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed. | 11-12-2015 |
20150322118 | RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH ENHANCED MEMBRANE LOCALIZATION - This invention relates to novel recombinant clostridial neurotoxins exhibiting increased membrane localization and to methods for the manufacture of such recombinant clostridial neurotoxins. These methods comprise the steps of inserting a nucleic acid sequence coding for a C2 domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the C2 domain in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased membrane localization. | 11-12-2015 |
20150335602 | IMPROVEMENT OF COGNITIVE FUNCTION IN PRETERM INFANTS THAT ARE SMALL FOR GESTATIONAL AGE - The present invention relates to the use of nutritional compositions enriched in glutamine to improve structural and functional brain development in preterm infants that born small for gestational age. | 11-26-2015 |
20150335708 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE - Disclosed herein are methods and compositions for treating or preventing Huntington's Disease. | 11-26-2015 |
20150343012 | TREATMENT OF MUSCULAR DYSTROPHY - The invention provides a compound capable of inhibiting ubiquitination for use in treating a disorder or symptom associated with reduced dystroglycan function in a subject. | 12-03-2015 |
20150361136 | NOVEL TRH BINDING SITE IN HUMAN CNS - The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterise the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders. | 12-17-2015 |
20150361140 | MITOCHONDRIAL TARGETING PEPTIDE - The present invention relates to a mitochondria targeting peptide, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain and an antioxidant is bound to the carboxyl terminus of the peptide, an antioxidant composition and a composition for preventing or treating Parkinson's disease including the fusion protein in which the antioxidant is bound, a recombinant polynucleotide in which a polynucleotide coding a protein transduction domain, a polynucleotide coding the peptide, and a polynucleotide coding an antioxidant protein are sequentially bound, to an expression vector including the polynucleotide, and to a transformed host cell including the expression vector. | 12-17-2015 |
20160015771 | METHOD OF TREATING OPTIC NERVE DAMAGE, OPHTHALMIC ISCHEMIA OR OPHTHALMIC REPERFUSION INJURY - The invention relates to a method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury including the step of administering an effective amount of a peptide comprising the sequence: GlyArgArgAlaAlaProGlyArgAibGlyGly (SEQ ID NO:1) or the sequence GlyArgArgAlaAlaProGlyArgAibGlyGly-HN2 (SEQ ID NO:2) to a subject in need thereof. | 01-21-2016 |
20160016996 | ANG-(1-7) DERVIATIVE OLIGOPEPTIDES AND METHODS FOR USING AND PRODUCING THE SAME - The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment. | 01-21-2016 |
20160030517 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE - Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1. | 02-04-2016 |
20160041189 | BIOMARKER FOR DETECTING WHITE MATTER STROKE, CONTAINING TOLL-LIKE RECEPTOR 2, AND MEDICAL USE OF TOLL-LIKE RECEPTOR 2 - The present invention relates to a biomarker composition for detecting white matter stroke, the biomarker composition containing a toll-like receptor 2 (TLR2), and a medical use using the TLR2. The TLR2 can be used as a biomarker for white matter stroke by defending against ischemic demyelination and oligodendrocyte death, and when targeting the TLR2, ischemic white matter stroke can be treated or prevented. | 02-11-2016 |
20160051689 | SUPRAMOLECULAR AGGREGATES COMPRISING MALEIMIDO CORES - The invention relates to a supramolecular aggregate of formula (VI) wherein A is an active substance, and X | 02-25-2016 |
20160082081 | METHODS AND COMPOSITIONS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS - Disclosed herein are methods and compositions for treating trinucleotide repeat disorders. | 03-24-2016 |
20160151442 | COMPOSITIONS COMPRISING NECROSIS INHIBITORS, SUCH AS NECROSTATINS, ALONE OR IN COMBINATION, FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION, THEREBY TREATING CNS DISORDERS | 06-02-2016 |
20160166633 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | 06-16-2016 |
20160166639 | GLYCOSYLATED PACAP/VIP ANALOGUES WITH ENHANCED CNS PENETRATION FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 06-16-2016 |
20160166640 | METHOD OF TREATING MYASTHENIA GRAVIS | 06-16-2016 |
20160175607 | SYSTEMS, METHODS AND COMPOSITIONS FOR OPTICAL STIMULATION OF TARGET CELLS | 06-23-2016 |
20160193291 | METHOD OF REGULATING NEURONAL AXON ELONGATION | 07-07-2016 |
20160193302 | LACTOFERRIN AND MEMORY AND LEARNING SPEED IN CHILDREN | 07-07-2016 |
20160250189 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | 09-01-2016 |
20160250276 | LISSENCEPHALY THERAPEUTIC AGENT | 09-01-2016 |
20160250288 | NERVE REGENERATING OR NERVE GROWTH-PROMOTING PHARMACEUTICAL COMPOSITION CONTAINING VAX PROTEIN AS ACTIVE INGREDIENT | 09-01-2016 |
20170233442 | PEPTIDYLYIC INHIBITOR TARGETING CAG-REPEAT RNA TOXICITY IN POLYGLUTAMINE DISEASES | 08-17-2017 |
20190142815 | Methylphenidate-Prodrugs, Processes of Making and Using the Same | 05-16-2019 |
20220133848 | METHODS AND COMPOSITIONS FOR RESTORING STMN2 LEVELS - The disclosure relates to compositions and methods for treating a disease or condition associated with a TDP-pathology or a decline in TDP-43 functionality in neuronal cells in a subject, and for identifying candidate agents to restore expression of a normal full-length or protein coding STMN2 RNA. | 05-05-2022 |